Feature | January 03, 2013

FDA Approves Abbott’s Next-Generation Xience Xpedition Drug-Eluting Stent

New stent offers enhanced deliverability, largest size matrix in U.S. market

abbott Xience Xpedition stent

January 3, 2013 — Abbott announced that the Xience Xpedition everolimus-eluting coronary stent system received U.S. Food and Drug Administration (FDA) approval and is launching immediately in the United States, providing physicians with a next-generation technology with the largest size matrix in the U.S. market. Xience Xpedition features a new stent delivery system designed to optimize deliverability, particularly in challenging coronary anatomies.

Samin K. Sharma, M.D., director of clinical and interventional cardiology, dean of international clinical affiliations, and president of the Mount Sinai Heart Network at Mount Sinai Medical Center, New York, was the first physician to implant a patient with Xience Xpedition in the United States.

"Xience Xpedition represents a powerful combination of deliverability, strong clinical data and broad availability of meaningful sizes, three factors that make this product well-suited to treat a wide range of patients," Sharma said. "The impact of the changes to the stent delivery system is particularly notable in patients with complex coronary anatomy. For these patients, physicians have a new technology to reach the blockage and restore blood flow with ease and confidence."

Abbott's Xience drug-eluting stents, including the newly approved Xience Xpedition, are the first and only drug-eluting stents in the U.S. market to be proven safe for direct stenting. Direct stenting, a technique in which the stent system is not preceded by another device (such as a balloon dilatation catheter) to prepare the lesion, has the potential to save time and resources in the catheterization laboratory. Xience Xpedition is supported by rclinical evidence from the Xience family of drug-eluting stents, including data from more than 45,000 patients across more than 100 studies, with long-term outcomes out to five years. Data have consistently shown an excellent safety profile for the Xience family of stents.

"The launch of Xience Xpedition in the United States will advance Abbott's worldwide market-leading position in drug-eluting stents," said John M. Capek, Ph.D., executive vice president, Medical Devices, Abbott. "Xience Xpedition leverages the strong clinical outcomes of Xience V and Xience Prime while providing important advantages in deliverability. With its redesigned stent delivery system and a full matrix of sizes, Xience Xpedition provides physicians with a comprehensive, trusted option to treat a broad range of patients with coronary artery disease."

Xience Xpedition will be available in the largest size matrix in the U.S. market, with both rapid exchange (RX) and over-the-wire (OTW) configurations, providing physicians with the most popular delivery platforms. The stent has diameters ranging from 2.25 mm to 4 mm, including a unique 3.25 mm diameter, and lengths from 8 mm to 38 mm, for more accurate vessel sizing.

For more information: www.abbott.com

Related Content

Million Hearts Cardiovascular Disease Risk Reduction Model, CMS, reduce heart attacks and strokes, participants
News | Patient Engagement| July 22, 2016
July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states,
heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
Absorb, bioresorbable stent, BVS
Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth revolution of inte
Sponsored Content | Videos | Inventory Management| July 19, 2016
You have bigger priorities than managing inventory.
Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable| July 19, 2016
Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery...
Medtronic, In.Pact Admiral drug coated balloon, DCB, FDA approval, 150 mm length
Technology | Drug-Eluting Balloons| July 18, 2016
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon...
3-D OCT

A 3-D OCT rendering of a stented vessel segment created on St. Jude Medical's Ilumien Optis OCT system. 

Feature | Angiography| July 15, 2016 | Dave Fornell
While angiographic X-ray fluoroscopy systems are the workhorse for transcatheter cardiovascular interventional proced
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters| July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
radial access, inserting stents, JACC Cardiovascular Interventions study
News | Radial Access| July 13, 2016
A new study in JACC: Cardiovascular Interventions supports access through the wrist, or radial access, as the default...
Toshiba, Infinix, 4DCT, CT-Angio

Toshiba’s Infinix 4DCT combines an Infinix Elite angiography system an Aquilion One Vision edition CT system. It allows clinicians to plan, treat and verify in a single clinical setting. The CT system is capable of capturing an entire organ in one rotation with 640 slices and 16 cm of anatomical coverage. 

Feature | Angiography| July 12, 2016 | Dave Fornell
Angiographic imaging system vendors have developed new technologies to address emerging cath lab trends, including th
Overlay Init